Kyverna Therapeutics, Inc. financial data

Symbol
KYTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5980 Horton Street, Suite 550, Emeryville, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.1M shares
Common Stock, Shares, Outstanding 43.1M shares
Weighted Average Number of Shares Outstanding, Basic 43.1M shares +6772%
Weighted Average Number of Shares Outstanding, Diluted 43.1M shares +6772%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 27.3M USD +163%
General and Administrative Expense 6.11M USD +111%
Operating Income (Loss) -33.4M USD -151%
Nonoperating Income (Expense) 4.63M USD +2095%
Net Income (Loss) Attributable to Parent -28.8M USD -120%
Earnings Per Share, Basic -0.67 USD/shares +96.8%
Earnings Per Share, Diluted -0.67 USD/shares +96.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 132M USD +146%
Marketable Securities, Current 215M USD
Cash, Cash Equivalents, and Short-term Investments 346M USD
Assets, Current 349M USD
Property, Plant and Equipment, Net 3.37M USD
Operating Lease, Right-of-Use Asset 7.83M USD
Other Assets, Noncurrent 1.21M USD
Assets 363M USD
Accounts Payable, Current 4.86M USD
Liabilities, Current 23.5M USD
Operating Lease, Liability, Noncurrent 5.72M USD
Liabilities 29.6M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -37K USD
Retained Earnings (Accumulated Deficit) -192M USD
Stockholders' Equity Attributable to Parent 334M USD
Liabilities and Equity 363M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.5M USD -123%
Net Cash Provided by (Used in) Financing Activities 338M USD
Net Cash Provided by (Used in) Investing Activities -123M USD -1000%
Common Stock, Shares Authorized 490M shares
Common Stock, Shares, Issued 43.1M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 190M USD +9137%
Interest Paid, Excluding Capitalized Interest, Operating Activities 44K USD 0%
Operating Lease, Liability 8.59M USD
Payments to Acquire Property, Plant, and Equipment 543K USD +1839%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28.8M USD -120%
Lessee, Operating Lease, Liability, to be Paid 9.68M USD
Property, Plant and Equipment, Gross 6.39M USD
Operating Lease, Liability, Current 2.87M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.05M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.56M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.09M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 446K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Operating Lease, Payments 809K USD +34.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 482K USD +22.3%
Share-based Payment Arrangement, Expense 1.28M USD +188%
Interest Expense 39K USD -15.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares